Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02576509 · ClinicalTrials.gov registry record · Phase 3

An Investigational Immuno-therapy Study of Nivolumab Compared to Sorafenib as a First Treatment in Patients With Advanced Hepatocellular Carcinoma

A Phase 3 study of Hepatocellular Carcinoma, sponsored by Bristol-Myers Squibb.

Completed
Registry status
Phase 3
Development phase
743
Enrollment target
20
Study locations

NCT02576509 is a Phase 3 study of Hepatocellular Carcinoma that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 743 participants, above the 252-participant average among 145 other Hepatocellular Carcinoma trials with a reported enrollment target (195% higher). The trial reports 20 study locations across 13 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02576509, a Phase 3 study of Hepatocellular Carcinoma, has completed, sponsored by Bristol-Myers Squibb.

COMPLETED
Registry status
Phase 3
Development phase
743 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to determine if nivolumab or sorafenib is more effective in the treatment of Advanced Hepatocellular Carcinoma.

Conditions Studied

Hepatocellular Carcinoma

Interventions

  • DRUG Nivolumab
  • DRUG Sorafenib

Study Locations (20)

California

  • Local Institution - 0020 - Los Angeles
  • Local Institution - 0015 - San Francisco
  • Local Institution - 0084 - San Francisco

Texas

  • UT Southwestern Medical Center - Dallas
  • Local Institution - 0017 - San Antonio
  • Scott & White Memorial Hospital And Clinic - Temple

New York

  • Local Institution - 0083 - New York
  • Local Institution - 0093 - New York

Pennsylvania

  • Local Institution - 0095 - Philadelphia
  • Local Institution - 0019 - Philadelphia

Washington

  • Local Institution - 0026 - Seattle
  • University of Washington - Seattle Cancer Care Alliance - Seattle

Alabama

  • Local Institution - 0066 - Birmingham

Illinois

  • Local Institution - 0061 - Chicago

Louisiana

  • Ochsner Clinic Foundation - New Orleans

Trial Details

FieldValue
Enrollment Target 743 participants
Start Date 2015-12-07
Est. Completion 2024-02-07
Phase Phase 3

Sponsor

Bristol-Myers Squibb

1,025 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02576509

The ClinicalTrials.gov registry entry for NCT02576509 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 743 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 252-participant average among 145 other Hepatocellular Carcinoma trials with a reported enrollment target (195% higher). The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Hepatocellular Carcinoma appearing as the primary indexed condition, and to 2 interventions - of which Nivolumab is the first listed.

NCT02576509 reports 20 study locations spanning 13 distinct geographic areas - top geographies include California, Texas, New York.

Frequently Asked Questions

What is clinical trial NCT02576509 about?

NCT02576509 is a clinical study titled "An Investigational Immuno-therapy Study of Nivolumab Compared to Sorafenib as a First Treatment in Patients With Advanced Hepatocellular Carcinoma". The purpose of this study is to determine if nivolumab or sorafenib is more effective in the treatment of Advanced Hepatocellular Carcinoma.

What is the current status of trial NCT02576509?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 743 participants. The study started on 2015-12-07. Estimated completion is 2024-02-07.

What conditions does trial NCT02576509 study?

This clinical trial studies the following conditions: Hepatocellular Carcinoma.

What interventions are being tested in trial NCT02576509?

The interventions under investigation include: Nivolumab (DRUG), Sorafenib (DRUG).

Who is sponsoring clinical trial NCT02576509?

This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02576509 being conducted?

This trial has 20 study locations across Alabama, California, Illinois, Louisiana, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Hepatocellular Carcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Hepatocellular Carcinoma

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.